
Psychosomatics 48:205-210, June 2007
doi: 10.1176/appi.psy.48.3.205
© 2007 Academy of Psychosomatic Medicine
Tamoxifen Treatment and New-Onset Depression in Breast Cancer Patients
Kelly C. Lee, Pharm.D., BCPP,
G. Thomas Ray, M.B.A.,
Enid M. Hunkeler, M.A., and
Patrick R. Finley, Pharm.D., BCPP
Received March 22, 2006; revised July 28, 2006; accepted August 8, 2006. From Loma Linda Univ.; Kaiser Permanente Division of Research; Univ. of California at San Francisco. Send correspondence and reprint requests to Kelly C. Lee, Pharm.D., BCPP, Assistant Professor, Pharmacy Practice, Loma Linda Univ. School of Pharmacy, 11262 Campus St., West Hall 1333, Loma Linda, CA 92350. e-mail: kclee{at}llu.edu
© 2007 The Academy of Psychosomatic Medicine
The authors conducted a retrospective cohort study of female patients diagnosed with breast cancer (BRCA), evaluating the risk of new-onset depression associated with tamoxifen treatment among those with estrogen receptor-positive (ER+) tumors, versus estrogen receptor-negative (ER) tumors, who were not receiving tamoxifen. A total cohort of 2,943 patients was identified. The hazard-ratio for new-onset depression in the tamoxifen group was nonsignificant. A post-hoc analysis revealed that chemotherapy and ER+ status were significantly and independently associated with an increased risk for developing depression.
This article has been cited by other articles:

|
 |

|
 |
 
J. T. PALMER and J. L. PAYNE
Stabilization of Hypomania Following Initiation of Tamoxifen
Am J Psychiatry,
May 1, 2008;
165(5):
650 - 651.
[Full Text]
[PDF]
|
 |
|
Get information about faster international access.
a>
Privacy Policy
Copyright © 2007
Academy of Psychosomatic Medicine.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|